Trial Profile
A Randomized, Controlled, Double-Blind, Phase 3 Study to Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Jun 2022
Price :
$35
*
At a glance
- Drugs Folic acid (Primary) ; Infliximab (Primary) ; Methotrexate (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Celltrion
- 04 Jun 2022 Results assessing equivalence of efficacy and comparing PK and safety profiles of CT-P13 and China-approved infliximab, presented at the 23rd Annual Congress of the European League Against Rheumatism.
- 13 Sep 2021 Status changed from active, no longer recruiting to completed.
- 30 Jul 2020 Planned End Date changed from 1 Dec 2020 to 30 Jun 2021.